Health :: Hostile men have poorer lung function
Men with short fuses may also be short of breath linking hostile temperament to poorer lung function.
People
DNA :: NHGRI Aims to Make DNA Sequencing Faster, More Cost Effective
Bethesda, Md. ? The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), today announced the latest round of grant awards totaling more than $13.3 million to speed the development of innovative sequencing technologies that reduce the cost of DNA sequencing and expand the use of genomics in medical research and health care.
Muscular Dystrophy :: Drug Trichostatin A (TSA) Can Counteract Muscular Dystrophy
Scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other institutions have demonstrated for the first time that a single drug can rebuild damaged muscle in two strains of mice that develop diseases comparable to two human forms of muscular dystrophy. This advance, which is reported online in Nature Medicine, is the latest from a research collaboration that began several years ago by the teams of Vittorio Sartorelli, M.D., at NIAMS and Pier Lorenzo Puri, M.D., Ph.D., now at Dulbecco Telethon Institute (DTI) in Rome, Italy and The Burnham Institute in La Jolla, Calif.
Irritable Bowel Syndrome :: Traveller’s diarrhoea may raise risk of IBS
People who experience traveller’s diarrhoea appear to be at significantly increased risk of subsequently suffering from irritable bowel syndrome (IBS), a condition characterised by abdominal pain, bloating, diarrhoea, and constipation.
Insomnia :: Caffeine more disruptive for daytime sleep
Caffeine has a stronger disruptive effect on daytime, catch-up sleep after a night of sleep deprivation.
Schizophrenia :: Solvay pharmaceuticals and Wyeth – new drug for bifeprunox to treat schizophrenia
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for bifeprunox, an investigational atypical antipsychotic for the treatment of schizophrenia.
Smoking :: Nabi biopharmaceuticals completes enrollment in nicvax phase iib ‘proof-of-concept’ clinical trial
Nabi Biopharmaceuticals (Nasdaq: NABI) today announced it has completed enrollment for its Phase IIB “proof-of-concept” study for NicVAX(R) (Nicotine Conjugate Vaccine), the company’s novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007.
Obesity :: Manhattan pharmaceuticals – oral oleoyl-estrone clinical program to include morbidly obese
Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.
Pregnancy :: Next-generation contraceptive patch by Agile Therapeutics
Agile Therapeutics, a pharmaceutical development company focused on innovative transdermal products, is developing the next generation of contraceptive patches, one that is designed to deliver low doses of birth control hormones over a seven-day period.
Malaria :: John mcneil named scientific director of path malaria vaccine initiative
The PATH Malaria Vaccine Initiative today announced the appointment of John G. McNeil, MD, MPH, as scientific director, effective immediately. Dr. McNeil will have principal responsibility for directing MVI’s early-stage vaccine development efforts and for shaping and managing MVI’s overall candidate vaccine portfolio.